Ally Bridge Group’s Atea Pharmaceuticals AVIR Stock Holding History

Ally Bridge Group’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-962,694	Closed	-$4.63M	–	23
2022 Q4	$4.63M	Buy	962,694 +602,694	+167%	+$3.05M	4.5%	8
2022 Q3	$2.05M	Buy	+360,000	New	+$2.76M	1.35%	25
2021 Q3	–	Sell	-373,288	Closed	-$8.02M	–	33
2021 Q2	$8.02M	Sell	373,288 -530,400	-59%	-$15.9M	1.99%	23
2021 Q1	$55.8M	Sell	903,688 -113,000	-11%	-$7.63M	10.7%	2
2020 Q4	$42.5M	Buy	+1,016,688	New	+$32.8M	7.28%	3

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ally Bridge Group's AVIR Position: Q1 2023 in Review

Ally Bridge Group sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 962,694 shares — an estimated $4.63M sold.

Ally Bridge Group first reported a position in AVIR in Q4 2020 and held it in 5 quarters. The position peaked at $55.8M in Q1 2021. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

Ally Bridge Group reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ally Bridge Group sold 962,694 Atea Pharmaceuticals shares in Q1 2023, an estimated $4.63M.
Ally Bridge Group first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Ally Bridge Group's Atea Pharmaceuticals position peaked at $55.8M in Q1 2021.
130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.